VEGFER-2 INHIBITORS AND QUINAZOLINE-BASED ANTICANCER AGENTS | ||||
| Al-Azhar Journal of Pharmaceutical Sciences | ||||
| Volume 68, Issue 2, September 2023, Page 111-129 PDF (578.41 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ajps.2023.332170 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Helmy Sakr  1; Islam Otify2; Rezk R Ayyad2; Alaa Elwan2
| ||||
| 1Department of Pharmaceutical Medicinal Chemistry & Drug Design, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt | ||||
| 2Department of Pharmaceutical Medicinal Chemistry & Drug Design, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt | ||||
| Abstract | ||||
| Inhibitors of vascular endothelial growth factor receptor -2 (VEGFR-2) are crucial biological targets for the development of novel anticancer medications. Quinazoline also plays an important role as one of the building elements of numerous anticancer drugs. Thus, a review of the literature on VEGFR-2 inhibitors and Quinazoline-based anticancer medicines has been completed. We introduced VEGFR-2 inhibitors now undergoing clinical evaluation, such as Gefitinib, Erlotinib, Vandetanib, Afatinib, Lenvatinib, Cabozantinib, Sorafenib and Regorafenib in our survey. Additionally, VEGFR-2 inhibitors that are under development were introduced. | ||||
| Keywords | ||||
| Vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors; Quinazoline; Anti-cancer agents | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 83 PDF Download: 154 |
||||
